Fewer than 10% of individuals who could benefit from obesity jabs like Wegovy can access them, states the WHO as it publishes its first advice on the drugs.
Given over a billion people worldwide currently classified as obese, it is advocating for broader and more equitable access to GLP-1 medication.
According to projections, over two billion could be obese by 2030 unless action is taken.
"The latest guidelines affirms that excess weight is a long-term condition that can be treated with comprehensive and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are key barriers to universal availability to the treatments that can assist patients in reducing considerable weight, notes the body.
Even under the current best projected scenario, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of eligible patients, per the health organization.
The guideline calls on nations and manufacturers to widen access, via strategies like voluntary licensing.
A patent on the active ingredient – the core ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
GLP-1 drugs mimick a natural hormone to slow digestion, reduce hunger and boost satiety so users consume fewer calories.
Patients usually start to lose weight after several weeks of starting on the weekly injections.
Research indicates people may regain a significant portion a year later of stopping the medication, when their usual hunger return.
To be carrying excess weight raises your chance for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight impacts people in every country and was linked to millions of fatalities worldwide in 2024, per the WHO.
A tech journalist and digital strategist with over a decade of experience covering emerging technologies and business innovation across Europe.
Allen Warren